Akeso Biopharma Initiates Phase III Study for Ivonescimab in Advanced Biliary Tract Cancer

Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, control...

November 01, 2024 | Friday | News
Eisai and Biogen Showcase Promising Long-Term Data for Lecanemab in Early Alzheimer’s Disease at CTAD 2023

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 01, 2024 | Friday | News
Roche Unveils Promising Data for Elecsys Amyloid Plasma Panel in Alzheimer’s Diagnosis at CTAD 2024

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...

November 01, 2024 | Friday | News
Novartis Secures FDA Accelerated Approval for Scemblix® in Newly Diagnosed CML Patients

Novartis announced that Scemblix® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients wit...

October 30, 2024 | Wednesday | News
RemeGen's Taicercept® for Generalized Myasthenia Gravis Receives Priority Review from China’s Drug Administration

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...

October 29, 2024 | Tuesday | News
AstraZeneca’s Fasenra Receives EU Approval as Add-On Treatment for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...

October 29, 2024 | Tuesday | News
RiboX Therapeutics Secures FDA Clearance for First-Ever Circular RNA Therapy RXRG001 in Phase I/IIa Study

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics...

October 28, 2024 | Monday | News
Kind Pharmaceutical Secures FDA Orphan Drug Designation for Sickle Cell Disease Treatment AND017

Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...

October 28, 2024 | Monday | News
PROVISION Study Reveals FFRangio's Advantages Over Traditional Wire-Based FFR at TCT 2024

The Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place at the Walter E. Washington Convent...

October 28, 2024 | Monday | News
Adona Medical Achieves Milestone with First-in-Human Use of Novel Interatrial Shunt for Heart Failure

Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced the successful first-in-human use of ...

October 28, 2024 | Monday | News
European Commission Approves KEYTRUDA for New Indications in Gynecologic Cancers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for K...

October 25, 2024 | Friday | News
Eli Lilly’s Donanemab Receives MHRA Approval for Alzheimer's Treatment in Great Britain

Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...

October 24, 2024 | Thursday | News
Pfizer Expands Pneumococcal Vaccine Recommendations for Adults 50 and Older Following CDC Advisory Committee Vote

Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP)...

October 24, 2024 | Thursday | News
Interius BioTherapeutics Doses First Patient in Groundbreaking Trial of INT2104, a First-in-Class In Vivo CAR Gene Therapy

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target...

October 23, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close